CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
These re-agent and diagnostic test kits come with 99.7% accuracy
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Acute therapies continue to report strong growth compared to chronic ones.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Subscribe To Our Newsletter & Stay Updated